Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy.

Oslo University Hospital, Oslo, Norway.

Survival: monthsCountry:Norway
Toxiciy Grade:4City/State/Province:Oslo
Treatments:ChemotherapyHospital:Oslo University Hospital
Drugs:Journal:Link
Date:Oct 2012

Description:

Patients:
This phase 3 study involved previously untreated advanced ovarian cancer patients who were divided into two separate treatment groups. Group A consisted of 445 patients with a median age of 57 years. Group B had 442 patients with a median age of 58 years.

Treatment:
Patients in group A were treated with the chemotherapy agents carboplatin, paclitaxel, and epirubicin.

Patients in group B were treated with the chemotherapy agents carboplatin and paclitaxel.

Toxicities:
The most severe toxicities in group A were of grade 4 and included vomiting and anemia. Grade 3 febrile neutropenia and nausea were also reported.

The most severe toxicities in group B were of grade 4 and included allergic reaction and anemia. Grade 3 joint pain was also reported.

Results:
The median overall survival rates for groups A and B were 42.4 and 40.2 months, respectively.

Support:
This study was supported by Pharmacia-Upjohn.

Correspondence: Dr. G. B. Kristensen; email: gunnar.b.kristensen@gmail.com



Back